Brand disclaimer image 1 Brand disclaimer image 2

Ozempic® (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with:2

  • diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance
  • metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control
  • metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control
  • metformin or a sulfonylurea and a sodium-glucose cotransporter 2 inhibitor (SGLT2i), when diet and exercise plus metformin or a sulfonylurea, in addition to an SGLT2i, do not achieve adequate glycemic control
  • basal insulin with metformin, when diet and exercise plus basal insulin with metformin do not achieve adequate glycemic control

Please consult the Product Monograph at OzempicPM-E.ca or here for more information on:

  • Contraindications in personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), and pregnancy or breastfeeding
  • A serious warning on risk of thyroid C-cell tumours
  • Other relevant warnings and precautions relating to intramuscular administration, CV effects (increased heart rate; PR interval prolongation), hypoglycemia with concomitant use of insulin secretagogues or insulin, use with other incretin drugs, hepatic insufficiency, pancreatitis, hypersensitivity, diabetic retinopathy (in patients with history of disease, monitor for progression), and renal impairment (severe GI adverse reactions warrant monitoring of renal function; use in end-stage disease)
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions
Continue

* Coverage criteria: As add-on therapy for the treatment of type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on: a sufficient trial (i.e., a minimum of 6 months) of metformin, AND a sulfonylurea, AND for whom insulin is not an option; OR for whom these products are contraindicated. Special authorization may be granted for 24 months.

 

  Comparative clinical significance unknown.
CV, cardiovascular; GI, gastrointestinal; GLP-1 RA, glucagon-like peptide-1 receptor agonist.

 

ADBL, Alberta Drug Benefit List.

Reset password

Reset password

Your password was updated successfully. You can now  Log in

{{submitErrorMsg}}